Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Average Recommendation of "Buy" by Analysts

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) has been given a consensus recommendation of "Buy" by the nine ratings firms that are presently covering the stock, Marketbeat reports. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $15.97.

A number of research analysts have issued reports on the stock. Leerink Partnrs raised shares of Voyager Therapeutics to a "strong-buy" rating in a report on Wednesday, October 16th. HC Wainwright reissued a "buy" rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research note on Monday, January 27th. Cantor Fitzgerald started coverage on shares of Voyager Therapeutics in a research note on Friday, January 10th. They set an "overweight" rating and a $5.73 price objective for the company. Canaccord Genuity Group reissued a "buy" rating and set a $14.00 price objective on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Finally, Citigroup started coverage on shares of Voyager Therapeutics in a research note on Monday, December 2nd. They set a "buy" rating and a $12.00 price objective for the company.

Voyager Therapeutics Price Performance

Voyager Therapeutics stock traded down $0.18 during mid-day trading on Wednesday, reaching $5.42. The company had a trading volume of 232,150 shares, compared to its average volume of 310,971. Voyager Therapeutics has a 1 year low of $4.99 and a 1 year high of $10.66. The company has a market capitalization of $296.09 million, a P/E ratio of 7.63 and a beta of 0.91. The stock's 50-day simple moving average is $5.77 and its 200-day simple moving average is $6.43.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The company had revenue of $24.63 million during the quarter, compared to analysts' expectations of $12.63 million. During the same period last year, the company posted ($0.59) earnings per share. On average, equities analysts forecast that Voyager Therapeutics will post -0.91 EPS for the current fiscal year.

Insiders Place Their Bets

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of Voyager Therapeutics stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total value of $36,725.00. Following the completion of the sale, the chief operating officer now directly owns 112,328 shares of the company's stock, valued at approximately $634,653.20. The trade was a 5.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last three months, insiders sold 10,778 shares of company stock valued at $58,548. Company insiders own 4.53% of the company's stock.

Hedge Funds Weigh In On Voyager Therapeutics

A number of hedge funds have recently made changes to their positions in VYGR. The Manufacturers Life Insurance Company boosted its holdings in shares of Voyager Therapeutics by 6.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 94,398 shares of the company's stock valued at $747,000 after purchasing an additional 5,365 shares during the last quarter. Hunter Perkins Capital Management LLC boosted its holdings in shares of Voyager Therapeutics by 3.3% in the 3rd quarter. Hunter Perkins Capital Management LLC now owns 64,040 shares of the company's stock valued at $375,000 after purchasing an additional 2,025 shares during the last quarter. Patriot Financial Group Insurance Agency LLC boosted its holdings in shares of Voyager Therapeutics by 7.0% in the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 136,894 shares of the company's stock valued at $801,000 after purchasing an additional 9,000 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Voyager Therapeutics by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company's stock valued at $61,000 after purchasing an additional 4,098 shares during the last quarter. Finally, Empowered Funds LLC boosted its holdings in shares of Voyager Therapeutics by 5.4% in the 3rd quarter. Empowered Funds LLC now owns 44,809 shares of the company's stock valued at $262,000 after purchasing an additional 2,278 shares during the last quarter. Institutional investors and hedge funds own 48.03% of the company's stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.